AIM ImmunoTech announced that the final patient has received their last dose in the Phase 2 DURIPANC trial testing Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer, ahead of schedule. The primary endpoint analysis will start in December 2026, with topline results expected in early 2027, and overall survival data anticipated by mid-2027. Encouraging earlier data showed Ampligen may significantly improve survival in certain patient subsets, supporting further Phase 3 trial planning. This milestone advances Ampligen toward potential regulatory submission for pancreatic cancer treatment.
Wall Street is expected to start August mostly higher with Dow Jones futures up 1% and S&P 500 gaining 0.5%, while Nasdaq futures remain flat following a recent tech rebound. Last month, technology stocks struggled, notably the Philadelphia Semicondu...
The FTSE 100 rose slightly to 10,888 points despite AstraZeneca shares dropping 7% due to merger talks with Bristol Myers Squibb, which face regulatory scrutiny. Shell agreed to sell its European onshore renewables business to TotalEnergies, reflecti...
AstraZeneca's shares fell 6% following reports of talks to acquire Bristol Myers Squibb, leaving analysts puzzled. Despite AstraZeneca's strong growth and innovation, brokers like Jefferies and UBS question the strategic timing and benefits of the de...
Compugen Ltd. reported progress in its MAIA-ovarian trial for platinum-sensitive ovarian cancer, expecting median progression-free survival data by Q1 2027, a potential milestone for its COM701 antibody. The company also highlighted advancements in p...
Alibaba unveiled its new AI model, Qwen3.8-Max, built on 2.4 trillion parameters, claiming performance comparable to top global AI systems. The model outperformed competitors in benchmarks and demonstrated autonomous coding by completing a software p...
